Liposphere’s patented knee joint
articulation injectable under development
CCoat® (Investigational Device) is targeted at coating the knee joint’s cartilage surface, providing a long-lasting mechanical “cushion” to enable ease of movement.
This cushioning function is achieved by utilizing robust yet elastic lipid-based spheres. These spheres hold surrounding water in a unique way, which in combination with their 3D morphology, offers high lubrication during joint articulation.
Disclaimer: Liposphere’s CCoat has not been reviewed or evaluated by the U.S. Food and Drug Administration. CCoat is not designed to diagnose, treat, cure, or prevent any disease and should not be used as a substitute for advice from a healthcare or medical professional.
Clinical
First-In-Human trials
showed that CCoat is safe, reduces pain for up to 6 months and
leads to improved functionality and sports recovery.
Quick Pain Relief and Improved Functionality
CCoat has demonstrated immediate and lasting benefits for people suffering from knee osteoarthritis, across key clinical parameters such as pain, mobility, physical activity and quality of life, indicating a comprehensive effect. Patients reported improvements considered significant by healthcare standards within 1 week of being administrated with CCoat, while reported clinical benefits lasted up to 6 months.
Using the KOOS scoring system (Knee injury and Osteoarthritis Outcome Score), patients reported that after being treated with a single Ccoat injection they were able to move better, feel better, and return to activities they had previously struggled with, due to pain reduction during these activities. All improvements were backed by statistically significant results, adding confidence to CCoat’s clinical credibility.
Safe and Innovative Biotechnolog
CCoat is a novel nonpyrogenic product, which is water-based and highly biocompatible. It is considered a medical device in the EU and does not contain any active ingredients or medicinal substances, as its function relies solely on its physical qualities as a boundary-forming product.
CCoat has an excellent safety profile, with no serious side effects or safety concerns reported during clinical studies – lower than the accepted safety thresholds defined in state-of-the-art standards for intra articular knee injections, including minimal joint swelling, injection site pain and stiffness.
MARKET RELEVANCE
The market standard non-surgical treatments are only partially meeting the needs of knee OA sufferers.
…which means that CCoat as an effective, structural boundary lubricant has the potential to capture significant share in the multi-billion dollar markets of human orthopaedics, sports injuries and pets.
Scaling up and growth
Clear path to growth and
significant valuation upside
Liposphere is currently raising Series B capital to accelerate CCoat® development and access the European market.
Only EU
Only Human Knee OA
And Elite Sports
Contact us
Would you like to contact us? Call us or send us a message
using the contact form – looking forward to hearing from you.
Liposphere Ltd.
Ha’arava 1
Giv’at Shmuel 5400804
Israel
Office: +972 (0) 732113227
E-Mail: contact@lipo-sphere.com
Follow us on LinkedIn